ATE330620T1 - Verwendung von midkin oder von anti-midkin antikörper - Google Patents

Verwendung von midkin oder von anti-midkin antikörper

Info

Publication number
ATE330620T1
ATE330620T1 AT98931102T AT98931102T ATE330620T1 AT E330620 T1 ATE330620 T1 AT E330620T1 AT 98931102 T AT98931102 T AT 98931102T AT 98931102 T AT98931102 T AT 98931102T AT E330620 T1 ATE330620 T1 AT E330620T1
Authority
AT
Austria
Prior art keywords
midkin
antibodies
midkine
inducible
heparin
Prior art date
Application number
AT98931102T
Other languages
English (en)
Inventor
Takashi Muramatsu
Tohru Takada
Kazuhiro Toriyama
Hisako Muramatsu
Original Assignee
Takashi Muramatsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takashi Muramatsu filed Critical Takashi Muramatsu
Application granted granted Critical
Publication of ATE330620T1 publication Critical patent/ATE330620T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT98931102T 1997-07-14 1998-07-14 Verwendung von midkin oder von anti-midkin antikörper ATE330620T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20533297 1997-07-14
JP20532097 1997-07-14

Publications (1)

Publication Number Publication Date
ATE330620T1 true ATE330620T1 (de) 2006-07-15

Family

ID=26515003

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98931102T ATE330620T1 (de) 1997-07-14 1998-07-14 Verwendung von midkin oder von anti-midkin antikörper

Country Status (10)

Country Link
US (1) US7390491B2 (de)
EP (1) EP0998941B9 (de)
JP (1) JP2010215673A (de)
KR (1) KR100571010B1 (de)
CN (1) CN1287852C (de)
AT (1) ATE330620T1 (de)
AU (1) AU756279B2 (de)
CA (1) CA2296409C (de)
DE (1) DE69835016T2 (de)
WO (1) WO1999003493A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329010A1 (en) * 1998-04-17 1999-10-28 Angiogenix Incorporated Therapeutic angiogenic factors and methods for their use
WO2000010608A1 (en) * 1998-08-24 2000-03-02 Meiji Milk Products Co., Ltd. Preventives/remedies for arteriosclerosis and post-ptca reangiostenosis
US20060259026A1 (en) * 2005-05-05 2006-11-16 Baylis Medical Company Inc. Electrosurgical treatment method and device
US8221758B2 (en) 2003-03-06 2012-07-17 Cellmid Limited Anti-midkine antibody for preventing post-laparotomy adhesions
WO2004085642A1 (ja) * 2003-03-27 2004-10-07 Takashi Muramatsu 関節炎関連遺伝子及びこれの関節炎検査等への利用
EP1964574B1 (de) 2005-11-14 2016-09-07 Cellmid Limited Verfahren zur behandlung oder prävention von krankheiten im zusammenhang mit funktionalen störungen der regulatorischen t-zelle
WO2008059616A1 (en) 2006-11-14 2008-05-22 Medical Therapies Limited Antibody recognizing c-domain of midkine
ZA200903562B (en) * 2006-11-14 2010-07-28 Ribomic Inc Aptamer against midkine and use thereof
WO2010074218A1 (ja) * 2008-12-25 2010-07-01 株式会社イーベック 抗ヒトミッドカイン抗体
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
US9624294B2 (en) 2011-03-14 2017-04-18 Cellmid Limited Antibody recognizing N-domain of midkine
US9840552B2 (en) 2012-07-30 2017-12-12 National University Corporation Nagoya University Monoclonal antibody against human midkine
KR101985300B1 (ko) * 2016-07-19 2019-06-03 삼성전자주식회사 미드카인 저해제를 포함하는 뇌종양 치료 또는 예방용 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206223A (en) 1986-06-26 1993-04-27 Yeda Research And Development Co. Ltd. Method for inhibiting heparanase activity
IL79254A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
US5210026A (en) 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
JPH06507635A (ja) 1991-05-02 1994-09-01 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 病理学的過程の予防および／または治療用組成物
EP0535336A3 (en) * 1991-09-30 1993-05-19 American Cyanamid Company Mk protein as cell growth inhibitor
US5461029A (en) * 1992-04-24 1995-10-24 American Cyanamid Company Method of treating herpes viral infections using HBNF and MK proteins
AU7205894A (en) * 1993-06-08 1995-01-03 Neogenix, Inc. Purified natural and synthetic compounds for the treatment of osteoarthritis
DE69621528T2 (de) 1995-02-07 2003-01-16 Shiseido Co. Ltd., Tokio/Tokyo Anti-inflamatorische agenzien
JPH08277224A (ja) * 1995-02-07 1996-10-22 Shiseido Co Ltd 抗炎症剤
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
JPH0995454A (ja) 1995-10-02 1997-04-08 Meiji Milk Prod Co Ltd 抗潰瘍組成物
WO1998001151A1 (en) 1996-07-10 1998-01-15 Meiji Milk Products Co., Ltd. Novel use of mk family as hematopoietic factor

Also Published As

Publication number Publication date
CN1306435A (zh) 2001-08-01
EP0998941A1 (de) 2000-05-10
WO1999003493A1 (en) 1999-01-28
DE69835016D1 (de) 2006-08-03
EP0998941B9 (de) 2007-03-14
CA2296409A1 (en) 1999-01-28
EP0998941A4 (de) 2004-05-12
CN1287852C (zh) 2006-12-06
DE69835016T2 (de) 2007-06-28
EP0998941B1 (de) 2006-06-21
AU8131098A (en) 1999-02-10
US20030072739A1 (en) 2003-04-17
US7390491B2 (en) 2008-06-24
JP2010215673A (ja) 2010-09-30
AU756279B2 (en) 2003-01-09
KR20010021814A (ko) 2001-03-15
KR100571010B1 (ko) 2006-04-13
CA2296409C (en) 2010-05-18

Similar Documents

Publication Publication Date Title
ATE330620T1 (de) Verwendung von midkin oder von anti-midkin antikörper
DE3667378D1 (de) Verwendung von n-(4-phenoxy-2,6-diisopropylphenyl)-n'-tert.butylthioharnstoff zur bekaempfung von weissen fliegen.
DE69008423D1 (de) Dynamische Fixierung von Schweinsaortaklappen.
EP0963197A4 (de) Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten
DE69629209D1 (de) Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
FI946004A0 (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
DE69434223D1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
DE3788984D1 (de) Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.
DE69941800D1 (de) Salze von Liponsaürederivaten und deren Verwendung bei der Behandlung von Krankheiten
ATE103932T1 (de) Fusionsprotein bestehend aus gm-csf und il-3.
DE69001839D1 (de) 1-hydroxyvitamin d2-epimer und dessen derivate.
ES2058599T3 (es) Procedimiento para mejorar la eficacia de las toxinas de insectos.
DE3774858D1 (de) Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
DE69624707D1 (de) Therapeutische verwendung von 1-amino-3-(n,n-dimethylamino)-propyliden-1,1-bisphosphonsäure und ihre salze
DE69319576D1 (de) Verwendung von Furanonen wie Duftstoffe
BR9612074A (pt) Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas
ATE172721T1 (de) Aminosäurederivate und ihre verwendung als enkephalinase-inhibitoren
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
ATE222896T1 (de) Substituierte thiazoline und ihre verwendung zur bekämpfung von tierischen schädlingen
DK109590D0 (da) Biologisk aktivt protein
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
DE69227805D1 (de) Verwendung von Tri-n-Butylphosphat bei niedrigem pH in Lösungen von biologisch aktiven Proteinen für eine verbesserte viruzide Wirkung
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
DE3881270D1 (de) Verwendung von pyrrolidon-derivaten als antiamnetikum.
DE69017825D1 (de) Heilverfahren von Lebererkrankungen mit Verwendung von Pyrrol-Chinolin-Chinone-Triester und neue Pyrrol-Chinolin-Chinone-Triester.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties